Efficacy and safety of oral AMN107 [nilotinib] in adults with chronic myelogenous leukemia resistant and/or intolerant to imatinib mesylate therapy

Trial Profile

Efficacy and safety of oral AMN107 [nilotinib] in adults with chronic myelogenous leukemia resistant and/or intolerant to imatinib mesylate therapy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Actual number of patients (36) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top